Unlock stock picks and a broker-level newsfeed that powers Wall Street.
MCE - Delayed Quote EUR

Laboratorios Farmaceuticos Rovi, S.A. (ROVI.MC)

Compare
50.70
-0.75
(-1.46%)
As of 11:14:36 AM GMT+2. Market Open.
Loading Chart for ROVI.MC
  • Previous Close 51.45
  • Open 51.00
  • Bid 50.65 x --
  • Ask 50.75 x --
  • Day's Range 50.55 - 51.10
  • 52 Week Range 50.45 - 94.80
  • Volume 23,837
  • Avg. Volume 130,693
  • Market Cap (intraday) 2.593B
  • Beta (5Y Monthly) 0.49
  • PE Ratio (TTM) 18.99
  • EPS (TTM) 2.67
  • Earnings Date May 6, 2025 - May 12, 2025
  • Forward Dividend & Yield 1.10 (2.15%)
  • Ex-Dividend Date Jul 8, 2024
  • 1y Target Est 79.26

Laboratorios Farmaceuticos Rovi, S.A. manufactures, sells, and markets pharmaceutical products in Spain, European Union, OECD countries, and internationally. The company offers prescription products, including Ameride, Bertanel, Bluxam, Enoxaparin Rovi, Calcium Vitamine D3 Rovi, Exxiv, Prinvil, Rhodogil, Glufan, Hibor, Hirobriz Breezhaler, Neparvis, Medicebran, Medikinet, Mysimba, Orvatez, Tryptizol, Ulunar Breezhaler, and Volutsa. It also provides hospital products, such as Iomeron and Iopamiro, Multihance and Y Prohance, Sonovue, Empowercta+, Empowermr, and CT Express; catheter care under the Fibrilin brand; and Sodium Heparin Rovi. In addition, the company offers contract-manufacturing services comprising compounding, aseptic filling and terminal sterilisation, inspection, installation of safety devices, labelling, packaging, serialisation and aggregation, for different injectable pharmaceutical forms, such as prefilled syringes, vials and cartridges, as well as manufacturing and packaging services for solid products. Its products are used for cardiology, osteoarticular/women's health, anesthesia /pain, diagnostic imaging contrast agents, central nervous system, urology, endocrinology, respiratory, and primary healthcare areas. The company was incorporated in 1946 and is headquartered in Madrid, Spain. Laboratorios Farmaceúticos Rovi, S.A. is a subsidiary of Norbel Inversiones, S.L.

www.rovi.es

2,197

Full Time Employees

December 31

Fiscal Year Ends

Recent News: ROVI.MC

View More

Performance Overview: ROVI.MC

Trailing total returns as of 4/2/2025, which may include dividends or other distributions. Benchmark is IBEX 35... (^IBEX) .

YTD Return

ROVI.MC
17.89%
IBEX 35... (^IBEX)
15.56%

1-Year Return

ROVI.MC
37.32%
IBEX 35... (^IBEX)
21.47%

3-Year Return

ROVI.MC
18.22%
IBEX 35... (^IBEX)
56.78%

5-Year Return

ROVI.MC
140.92%
IBEX 35... (^IBEX)
102.80%

Compare To: ROVI.MC

Select to analyze similar companies using key performance metrics; select up to 4 stocks.

Statistics: ROVI.MC

View More

Valuation Measures

Annual
As of 4/1/2025
  • Market Cap

    2.63B

  • Enterprise Value

    2.72B

  • Trailing P/E

    19.27

  • Forward P/E

    --

  • PEG Ratio (5yr expected)

    --

  • Price/Sales (ttm)

    3.45

  • Price/Book (mrq)

    4.60

  • Enterprise Value/Revenue

    3.56

  • Enterprise Value/EBITDA

    13.09

Financial Highlights

Profitability and Income Statement

  • Profit Margin

    17.92%

  • Return on Assets (ttm)

    13.69%

  • Return on Equity (ttm)

    24.33%

  • Revenue (ttm)

    763.75M

  • Net Income Avi to Common (ttm)

    136.88M

  • Diluted EPS (ttm)

    2.67

Balance Sheet and Cash Flow

  • Total Cash (mrq)

    28.02M

  • Total Debt/Equity (mrq)

    19.67%

  • Levered Free Cash Flow (ttm)

    44.63M

Research Analysis: ROVI.MC

View More

Company Insights: ROVI.MC

Research Reports: ROVI.MC

View More

People Also Watch